Hangzhou Edcheng Pharmaceutical Technology Co., Ltd.

Primary objective To evaluate the overall survival (OS) efficacy of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment. Secondary objective To evaluate the progression-free survival (PFS) and other efficacy indicators of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment.

Primary study objective: Effect of a high-fat diet on the pharmacokinetics of AL8326 after oral administration of AL8326 tablets in healthy Chinese adult subjects. Secondary study objective: Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects.

Primary objective: To evaluate the safety and tolerability of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors, observe the occurrence of DLT, and determine the MTD and RP2D. Secondary objective: To preliminarily obtain the pharmacokinetic parameters of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors (only the first part). Preliminary evaluation of the effectiveness of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors